Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer
NCT04822298
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
3
Enrollment
INDUSTRY
Sponsor class
Stopped
Amgen made a business decision to discontinue AMG 160 20180273
Conditions
Non-small Cell Lung Cancer
NSCLC
Interventions
DRUG:
AMG 160
Sponsor
Amgen